Medivir to start Lipsovir phase 3 trial in July

By Elaine Rigoli

Tampa, Fla., June 12 - Medivir said planning for phase 3 clinical trials for Lipsovir (ME 609) has proceeded faster than expected and, as a result, the clinical trial has been brought forward by several months and will start in July.

Medivir said the aim is to enable a potential market authorization late in 2008.

Medivir also said positive efficacy data was shown in a preclinical model for chronic obstructive pulmonary disease (COPD).

Medivir said its new protease inhibitor shows a profound and significant efficacy in this disease model and effectively decreased the release of inflammatory biomarkers, which are characteristic for COPD.

The aim is to designate one or more candidate drugs for further clinical development. The project is on its way into the preclinical optimization phase.

Separately, Lipsovir recently obtained a strengthened and prolonged patent position in the United States, extending to 2020.

Medivir develops drugs against major, widespread diseases based on proteases as targets and is located in Huddinge, Sweden.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.